GSK And Pfizer Join Forces In New HIV-Focused Venture
This article was originally published in The Pink Sheet Daily
Executive Summary
ViiV Healthcare will market the two companies' combined portfolio of 10 HIV drugs while also taking over a 17-compound R&D operation.
You may also be interested in...
Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.
Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.
In Another Pfizer Fire Sale, VC-Backed Conatus Acquires Idun's Idle Assets
Launched in 2006 by Idun's former management team, San Diego startup Conatus buys back a familiar property at a rock-bottom price.